Abstract. Spectrophotometric heparin assays which are based on the catalytic effect of heparin on either the inactivation of thrombin or that of factor Xa by antithrombin III, were adapted for use in a laboratory batch analyzer. Optimal conditions were determined for assays using the chromogenic substrates Chromozym-Th and 5-2238 with thrombin, and 3-2222 with factor Xa. Inactivation of the clotting enzyme by antithrombin III was stopped by addition of chromogenic substrate. Assays thus obtained appeared to be applicable in a wider range of heparin concentrations and were less dependent on plasma antithrombin III concentration that known manual spectrophotometric methods. The best results were obtained with the methods based on thrombin inactivation and applying a logarithmic reference curve.
Introduction
Several spectrophotometric heparin assays have been described [1] [2] [3] [4] ; all are manual methods, some of which are claimed to be adaptable to automated analyzers. The aim of this study was to find an automated heparin assay suited for routine laboratory use that assesses the heparin level in the therapeutic range and above, and that is independent of the antithrombin III (AIIID level in the sample.
Since clinicians frequently aim at plasma heparin levels between about 200 and 800 U,/1, it was necessary that the reference curves used would cover that range. The methods should, however, also give acceptable estimates of the heparin level in case of oyerdosage, and thus the method should render reliable values above the higher limit (up to 1,500 u/l).
For ease of automatic data handling it was important that reference curves would meet a simple mathematical formula. Most authors [-3] reported their reference curves to be linear from 0 to 600 U of heparin/l plasma, and srggested dilution of samples at higher levels in order to obtain reliable estimates. As dilution is time consuming, however, it is impossible to diflerentiate immediately be-tween a small or a large overdose. Moreover, dilution changes reaction conditions since the ATIII in the sample is diluted as well. To find a calibration curve that covers a wider range of heparin concentrations, we included in our study the use ofa parabolic and a logarithmic fit through reference measurements.
Most amidolytic heparin assays published negate the influence of the plasma ATIII levels, and the influence of ATIII in the plasma on the outcome of the heparin determination has been reported to be moderate [l] . The linearity of the dose-response curves in the assay with Xa and 5-2222 was reported to be dependent on the use ofAtIII in the assay I I , 2].
Heparin is preferably measured under conditions of a molar excess of other reactants, i.e. ATIII and either thrombin or factor Xa. An excess of 1,000 times has been suggested as satisfactory [6] to obtain reactions dependent on heparin concentration only. Because heparin increases neutralization of factor Xa by ATIII about 1,300-fold, and that of thrombin about 2,000-fold [5] , a 1,000-fold excess of free AIIII, however, will bring the rates of enzyme inactivation by free ATIII and by the ATIII-heparin complex in the same order of magnitude.
Therefore, the contribution of free ATIII to the inactivation of enzyme may not be neglected a priori. Whether the concentration of free ATIII in the assay does influence the outcome of the test depends on the ratio of the concentration of the heparin-Atlll complex to that of free AIIII, hence on the amount of ATIII added.
Therefore, we studied the influence of various ATIII levels in heparinized plasmas on the outcome of the assays and determined analytical conditions to minimize this influence.
Materials
Citrated Plasma. By means of a vacuum system (Venoject) with a multi-sample needle, 1.8 ml blood was drawn from the antecubital vein and used for other purposes. Next, three tubes (Venoject, black stopper, 4.5 ml, 3.8olo tri-Na-citrate) were drawn and centrifuged (10 min, 3,500 S', 15 "C) within 15 min. The plasma thus obtained contained less than 3 X lOe plateletsil.
Pooled Plasma. Equal volumes of citrated plasma from 30 healthy donors were mixed and stored ar -70 'C in aliquots of I ml.
Heparin was obtained from ko, Emmen, Holland. According to the manufacturer, the solution contained 5,000 USP U/ml of the sodium salt. Dilutions were made with buflered saline (147 mi1 NaCl, 6.52mMNa2HPO4, 1.62 m,41KH2PO4, pH 7.35).
Antithrombin III from KabiVitrum, Amsterdam was used. The contents ofeach vial (10 U) were solved in 10 ml distilled water. One unit is defined as the activity found in I ml of pooled plasma.
Thrombin used was bovine thrombin from Roche, Basel. The contents ofeach vial (120 USP units) were dissolved in 2.40 ml distilled water. Before use I vol thrombin was diluted with 5 vol buffer.
Factor Xa used was bovine factor Xa from Kabi Vitrum, Amsterdam. The contents of each vial (71 nkat) were dissolved in 10 ml distilled water.
Heparin Kil.r. Coatest/Heparin was obtained from KabiVitrum, Amsterdam. TC-Heparin was obtained from Boehringer-Mannheim, Amsterdam. These assays were performed according to the instructions supplied for kinetic measurement (table I) .
Chromogenic substrates used were Tos-Giy-ProArg-pNA (Chromozym-Th, Boehringer-Mannheim, Amsterdam), Benz-Ile-Glu-Gly-Arg-pNA . HCI and H-D-Phe-Pip-Arg-pNA , 2HCl (5-2222 and. 5-2238 both from KabiVitrum, Amsterdam). Each ofthe substrates was dissolved in distilled water.
Bulfer for automated assays (pH 8.4 and I 0.2) contained di-Na-EDTA (7.5 mn{, Tris . HCI (50 mlr') and NaCl (175 mA4).
Methods
Assays were performed on a 'Corona' batch analyzer (Clinicon, Amsterdam). This analyzer has a built-in microprocessor that checks on the linearity of van Putten/van de Ruit/Beunis/Hemker change in optical density during the measuring period. Conditions were set so as to generate an error message on deviations of more than 2 milliextinctions from linear, i.e. at deviations larger than 2% ofthe slowest rate observed in practice. Prediluted plasma samples were fed into the instrument and there diluted in duplicate and pipetted into polystyrene cuvettes. The cuvette was transported into a tunnel ofconstant temperature and (after the preincubation time) Xa or IIa solution was added. After a programmed incubation time a chromogenic substrate solution was added and with a small delay the remaining Xa or IIa activity was measured. The change in absorbance was calculated, stored in memory and printed.
We varied the heparin assay conditions to suit the following demands: (l) Standard deviation ofthe reference measurements about the calculated reference line has to be less than 5 9o ofthe range covered. (2) At the highest heparin level measured, at least halfofthe original enzyme should be left at the end of the incubation time so as to ensure excess ofthis reactant dur- Table I The final procedures of the heparin assays are given in table I. Reference samples were made of pooled normal plasma spiked with known amounts of the heparin ofthe same batch as we desired to determine. Artifrcial variations in the ATIII level were simulated by variations in the amount added in the predilution stage, as indicated in table II. The reference curve was obtained by a logarithmic fit through reference measurements. Alternatively, a. linear and a parabolic fit were studied.
Results and Discussion
The spectrophotometric determination of heparin can most simply be explained as a reverse titration of clotting enzyme. a*s-5l--'as,
Kr)Kr where H = n.Ounn, A = antithrombin III, and E = enzyme (thrombin or Xa). Table II . Dilution procedure for reference samples fil1fo6rrgh ATIII is available in molecular excess (> 20x) over heparin in the Kabi heparin kit, we found enzyme inactivation to be strongly influenced by both the amount of AIIII and the amount of heparin at low heparin concentrations, whereas at high heparin concentrations ATIII appeared to be the main determinant of the test result ( fig. l) . As in the Boehringer kit the plasmas are tested without predilution, different ATIII levels are not easily simulated, but for this assay an even larger influence of AtIU may be expected because no extra ATIII is added.
The influence of ATIII is not explained by the titration model above, but it can be explained by a more complex model of the action of heparin as has been fottndby Markwardt and Walsmann [7] , and confirmed by others t8-101. In this complex model heparin 
Kz>Ka This extra reaction predicts a multiphase behavior of enzyme inactivation. In a first transient phase, concentrations of HA and HAE are built up. In a second steady phase, there is constant production of free heparin (H) and hence constant input in reaction l, and thus constant inactivation of enzyme as well. Next, reactions slow down by the increasing influence of decreasing ATIII and enzyme levels. In the transient and steady phase, enzyme inactivation is mainly dependent on the heparin concentration and little on the concentrations of ATIII or enzyme> whereas in the next phase the reactant present in the lowest concentration is rate limiting. Therefore, heparin determinations should be carried out in the transient and steady phase, as much as practically possible.
The transient steady phase model predicts that the ATIII present in the assay as well as the incubation time remain important. Any heparin determination should therefore be tested on its dependency on ATIII concentration and on incubation time. So we studied the influence of various incubation periods and of extra ATIII added.
We found the inactivation of enzyme to be in hrst approximation linearly related to the incubation time, both with and without heparin ( fig.2a-<) .In the absence of heparin, only reaction 3 is responsible for enzyme inactivation. In the presence of heparin, enzyme inactivation is dependent on heparin concentration. Extrapolation to zero time ( fig.2) indicates the occurrence ofa transient phase of rapid, heparin-dependent enzyme inactivation. The system therefore behaves as predicted by the second model.
During the second phase the rate of enzyme inactivation is governed by the rate of heparin release from the ATlll-enzyme-heparin complex. The enzyme kinetics of this mechanism resemble those of active site titration of hydrolytic enzymes I l]. As a practical consequence, heparin will continue to bind ATIII to the clotting enzyme during the incubation time. To ensure that the reaction rate is suffrciently independent of the ATIII concentration, the latter reactant will have to be present in excess (80 times the concentration ofthe other reactant).
Still at higher heparin concentrations (above 600 Uil plasma in fig.4 ), a slight deviation ofthe linear shape ofthe reference ''L..:1,,i ,."--in:;':.;:i'j.-r3-: r*:5:j-;j-:i+:?.'r.
ir"'-:r'li ::1 ; i.:r'-.: line was observed. Because ATIII will be rate limiting in reactions I and 3, and the enzyme in reactions 2 and 3, while the velocity of reaction 4 is limited by the results of reaction 2 on the one hand and influences the velocity of reaction I on the other. it will be clear that the shape ofthe reference line can hardly be expected to be a simple one. The theoretically correct shape would be governed by at least 6 variables besides heparin (concentrations of enzyme and AIIII, reaction constants K1 through K6, temperature and incubation time). Trying to fit 6 (or more) variables to our data points would be both theoretically and practically unacceptable. Rather in these cases one resorts to treating the system as a black box and tries to find the reference curve that is most useful in practice (c.f. the logJog reference curve of the traditional bioassay). As most desk calculators and even many laboratory analyzers can handle formulas as a logarithmic and a parabolic frt through the reference points, we studied whether the latter two could improve accuracy of readings from the reference curve at higher heparin concentrations.
Enzyme inactivation by ATIII without heparin at the used concentration was about the same as the inactivation caused by increasing the concentration ofheparin by 150 U/l (frg. 2). So, variations in ATIII in the assay (A in eq. l-4) may have considerable influence on the result. Therefore, conditions in our assays were chosen so that the ATIII in the sample hardly contributed to the ATIII in the assay. In the assays based on thrombin inactivation, only a maximum of l/8 of the total ATIII present at the reaction originates from the sample. Increasing ATIII in the assay based on factor Xa inactivation, however, requires a comparably high concentration of factor Xa and thus large amounts of van Putten/van de RuiVBeunis/Hemker 3-2222 as well. Economical constraints on the use of these reactants forced us to limit the extra amount of ATIII to a factor 1, in tests based on factor Xa inactivation. This is the basis of the fact that assays with thrombin (and Chromozym-Th or 5-2238) are less influenced by various ATIII levels than assays with factor Xa (and 3-2222) are (table III) . In all assays some influence was found however. Acceptable results were obtained in a wider range of heparin concentrations with the three automated assays ttian with the manual kit methods.
Residual activity of thrombin and of factor Xa after the incubation time was approximately constant during at least 1 min after addition of substrate to the reaction mixture. This was concluded from the linearity of recordings ofthe absorbance (not shown) and from the fact that no error messages (indicating nonlinearity) were obtained. Since we measured not longer than until 28 s after the addition of the substrate, we neyer encoun-.. tered substrate exhaustion in the assavs. From the results shown in figure 2 , we conclude that there is a linear, time-related inactivation of enzyme during at least thrice the incubation time. Since the enzyme activity continuously decreases during incubation before adding substrate, but remains constant after this addition, we conclude that inactivation of enzyme ceased after addition of substrate solution. The inhibitory effect of synthetic substrates has been reported before [3, 8] . It could be the consequence ofgreater aflinity of the enzyme for the substrate than for AtIII. The Lineweaver-Burk plots shown in figure 3 suggest that V** rather than K* remains constant at various levels of inhibi; tor (chromogenic substrate) present at the inactivation of thrombin by AtI[. This favors the opinion of competitive inhibition of ATIII by the chromogenic substrate.
The deviation of the reference measurements about the calculated linear catbration line was smaller for the automated than for the manual methods ( fig.4) The results of the 9 measurements by each assay were read from the same reference line.
Automated Determination of Heparin with Cfuomogenic Substrates deviation is about the same for all methods. A linear fit after log transformation gives intermediate results (table IV) .
The parabolic calibration lines of the automated methods showed no horizontal part in the range 0-1,000 U/l(frg. 4). The manual methods, in contrast, revealed zero slope of the calibration line between 700 and 900 U/1. For reliable extrapolated estimations of heparin concentration in the range 1,000-1,500 U/1, the logarithmic equation may be applied for the automated methods ( mation on a moderate overdose, thus obtained, will be of more Yalue to clinicians and can be presented without the delay ofredetermination after dilution. With the other equations, no reliable estimate can be obtained in this range.
Dilution of plasma ATIII had considerable influence on the results of the original manual methods, as can be read from figure l. Table VI shows that up to 4O-fold dilution of samples by saline or buffer, hardly influences the result of the anti-thrombin-based test in the modifications here described. Therefore, even heparin concentrations ofup to 10,000 U/1, as used in open-heart surgery can be -monitored sulficiently with the automated methods with thrombin.
Several studies have shown a dilference in anti-Xa -effect and anti-Ila effect between heparins of different molecular weight or different origin. We found a catalytic action of the heparin we used, on both thrombin and Xa inactivation. It should be emphasized that for the constr,uction of reference curves the same heparin is to be used as that in the unknown samples. Both automated methods are subject to further investigation both for the determination of different heparins, and for the determination of heparin in actual patient plasmas.
In conclusion, it can be said that the auto_ mated spectrophotometric methods for hepa_ rin determination we present in this article are more reliable than the available manual chromogenic methods and allow heparin to be determined over a wider range. The meth_ ods based on thrombin inactivation are to be preferred over those using factor Xa inhibi_ tion because the antithrombin methods are hardly influenced by the plasma ATIII con_ centration.
